Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life

Blood (2013) 122 (21): 2877.

https://doi.org/10.1182/blood.V122.21.2877.2877

Published: 2013

Journal Articles

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Verena S Hoffmann, PhD, Doris Lindoerfer, Dipl.-Inf., Markus Pfirrmann, PhD, Susanne Saussele, MD, Andreas Hochhaus, MD, Jutta Engel, PhD, MD, Joelle Guilhot, PhD, Gianantonio Rosti, Jiri Mayer, MD, PhD, Karel Indrak, MD, Fausto Castagnetti, Anna Turkina, Andrey Zaritskey, MD, PhD, Juan Luis Steegmann, MD, PhD, Andrzej Hellmann, Noortje Thielen, MD, Francisco Cervantes, MD, PhD, Bengt Simonsson, MD, PhD, Adriana Colita, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Antonio Almeida, MD, PhD, Boris Labar, MD, PhD, David Marin, MD, Gert J. Ossenkoppele, MD PhD, Andrija Bogdanovic, Irina Dyagil, Kimmo Porkka, MD, PhD, Stephen O'Brien, Laimonas Griskevicius, Panagiotis Panagiotidis, MD, Josef Thaler, MD, Irena Zupan, MD, PhD, Sandra Lejniece, PhD, MD, Hele Everaus, MD, PhD, Tamás Masszi, MD, PhD, Frederiki Melanthiou, Rüdiger Hehlmann, Joerg Hasford, MD, Michele Baccarani, MD

Blood (2013) 122 (21): 2735.

https://doi.org/10.1182/blood.V122.21.2735.2735

Published: 2013

Journal Articles

Combination Of Lenalidomide, Dexamethasone and Cyclophosphamide as Treatment For The First Relapse Of Multiple Myeloma: Efficacy, Toxicity and Occurance Of Thyroid Abnormalities

Marta Krejci, MD, PhD, Zdenek Adam, Prof. MD, PhD, Ludek Pour, MD, PhD, Jana Pelcova, Jiri Mayer, MD, PhD

Blood (2013) 122 (21): 3233.

https://doi.org/10.1182/blood.V122.21.3233.3233

Published: 2013

Journal Articles

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Andrea Janikova, MD, PhD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Leos Kren, MD, PhD, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Jan Pirnos, MD, Milan Matuska, MD, PhD, Tomas Papajik, MD, PhD, ass. prof., Heidi Mocikova, MD, PhD, Samuel Vokurka, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4387.

https://doi.org/10.1182/blood.V122.21.4387.4387

Published: 2013

Journal Articles

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

Andrea Janikova, MD, PhD, Katerina Benesova, MD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Natasa Kopalova, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Samuel Vokurka, MD, PhD, Jan Pirnos, MD, Milan Matuska, MD, PhD, Heidi Mocikova, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4388.

https://doi.org/10.1182/blood.V122.21.4388.4388

Published: 2013

Journal Articles

SF3B1 Mutations Frequently Occur With Both ATM Mutations and TP53 Mutations In CLL Patients

Veronika Navrkalova, MSc., Jitka Malcikova, PhD, Barbara Kantorova, MSc., Ludmila Sebejova, Karla Plevova, MSc., Marek Mraz, MD, PhD, Michael Doubek, Yvona Brychtova, MD, PhD, Jana Smardova, MD, PhD, Jiri Mayer, MD, PhD, Sarka Pospisilova, Martin Trbusek, PhD

Blood (2013) 122 (21): 2868.

https://doi.org/10.1182/blood.V122.21.2868.2868

Published: 2013

Journal Articles

NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911)

Eugen Tausch, MD, Philipp Beck, Richard F. Schlenk, MD, Sabrina Kless, Christina Galler, Peter Hillmen, MB ChB, PhD, Fritz Offner, MD, Ann Janssens, MD, K Govindbabu, MD, Sebastian Grosicki, MD, Jiri Mayer, MD, PhD, Panagiotis Panagiotidis, MD, Susanne Danhauser-Riedl, MD, Astrid McKeown, PhD, Paul D P´B Winter, PhD, Ira V Gupta, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 527.

https://doi.org/10.1182/blood.V122.21.527.527

Published: 2013

Journal Articles

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Peter Hillmen, MB ChB, PhD, Tadeusz Robak, Ann Janssens, MD, K Govindbabu, MD, Sebastian Grosicki, MD, Jiri Mayer, MD, PhD, Panagiotis Panagiotidis, MD, Eva Kimby, MD, Anna Schuh, MD, Thomas Boyd, MD, Marco Montillo, MD, Astrid McKeown, PhD, Jodi L Carey, RN, BSN, Ira V Gupta, MD, Chai-Ni Chang, MS, Steen Lisby, MD, DMSc, Fritz Offner, MD

Blood (2013) 122 (21): 528.

https://doi.org/10.1182/blood.V122.21.528.528

Published: 2013

Journal Articles

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Jorge E. Cortes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD, Neil P. Shah, MD, PhD, Jiri Mayer, MD, PhD, Philip Rowlings, MD, Hirohisa Nakamae, MD, PhD, M. Brigid Bradley-Garelik, MD, Hesham Mohamed, MD, Hagop M. Kantarjian, MD, Giuseppe Saglio, MD

Blood (2013) 122 (21): 653.

https://doi.org/10.1182/blood.V122.21.653.653

Published: 2013

Journal Articles

Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma

Jan Walewski, MD, PhD, Ewa Paszkiewicz-Kozik, Agnieszka Warszewska, Gabriela Borsaru, Andreea Moicean, Andrzej Hellmann, Jiri Mayer, MD, PhD, Bernhard Hauns, Anna Mais, Stefan W. Henning, Bernd Hentsch

Blood (2011) 118 (21): 2675.

https://doi.org/10.1182/blood.V118.21.2675.2675

Published: 2011

Journal Articles

Pattern of Mir-155 and PU.1 Expression in CLL/SLL and Aggressive Lymphomas

Tomas Stopka, MD, PhD, Karin Vargova, Hana Huskova, Pavel Burda, PhD, Nikola Curik, Petra Vlckova, Vojtech Kulvait, Vit Pospisil, Filipp Savvulidi, Emanuel Necas, Marek Mraz, MD, Sarka Pospisilova, Dr, PhD, Jiri Mayer, MD, PhD, Josef Karban, Petra Obrtlikova, MD, PhD, Marek Trneny

Blood (2011) 118 (21): 4600.

https://doi.org/10.1182/blood.V118.21.4600.4600

Published: 2011

Journal Articles

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Blood (2010) 116 (21): 921.

https://doi.org/10.1182/blood.V116.21.921.921

Published: 2010

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

Journal Articles

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma

Bertrand Coiffier, MD, PhD, Evgenii Osmanov, MD, Xiaonan Hong, MD, Adriana Scheliga, MD, Jiri Mayer, MD, PhD, Fritz C Offner, MD, PhD, Simon A. Rule, MD, Adriana Teixeira, MD, Jan A Walewski, MD, PhD, DSc, Michael Crump, MD, FRCPC, Ofer Shpilberg, MD, MPH, Robert Hermann, MD, Sudha Parasuraman, MD, Eugene Zhu, PhD, Christopher Enny, BS, Panteli Theocharous, MSc, PhD, Helgi van de Velde, MD, PhD, Yusri Elsayed, MD, PhD, Pier Luigi Zinzani, MD, PhD

Blood (2010) 116 (21): 857.

https://doi.org/10.1182/blood.V116.21.857.857

Published: 2010

Journal Articles

Similar Efficacy of Thalidomide-Based and Bortezomib-Based Regimens In the First Relapse of 209 Multiple Myeloma Patients Previously Untreated with Novel Drugs

Marta Krejci, Evzen Gregora, Ivan Spicka, Vlastimil Scudla, Jan Straub, Jiri Minarik, Zdenek Adam, Andrea Krivanova, Ludek Pour, Lenka Zahradova, Jiri Mayer, MD, PhD, Roman Hajek

Blood (2010) 116 (21): 5027.

https://doi.org/10.1182/blood.V116.21.5027.5027

Published: 2010

Journal Articles

The Mystery of FDG-PET Avidity In Follicular Lymphoma. Does Microenvironment Play the Key Role?

Andrea Janikova, MD, PhD, Boris Tichy, Dr, Jana Supikova, Dr, Pavel Fabian, MD, PhD, Leos Kren, MD, PhD, Karol Bolcak, MD, David Salek, MD, Jozef Michalka, MD, Sarka Pospisilova, Dr, PhD, Jiri Mayer, MD, PhD

Blood (2010) 116 (21): 4138.

https://doi.org/10.1182/blood.V116.21.4138.4138

Published: 2010

Journal Articles

Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Michael Doubek, MD, PhD, Martin Simkovic, MD, Anna Panovska, MD, Monika Hrudkova, MD, David Belada, MD, PhD, Yvona Brychtova, MD, Jiri Mayer, MD, PhD, Lukas Smolej, M.D., Ph.D.

Blood (2010) 116 (21): 4629.

https://doi.org/10.1182/blood.V116.21.4629.4629

Published: 2010

Journal Articles

Gene-Expression Profile of Steroid-Refractory Acute Graft-Versus-Host Disease.

Jan Verner, PhD, Jitka Kabathova, Dr, Zbynek Zdrahal, Dr, Alexandra Tomancova, Jana Volejnikova, MD, Yvona Brychtova, MD, Sarka Pospisilova, Dr, PhD, Jiri Mayer, MD, PhD

Blood (2010) 116 (21): 4549.

https://doi.org/10.1182/blood.V116.21.4549.4549

Published: 2010

Journal Articles

Dasatinib Promotes BIM Dependent Apoptosis Via MEK/ERK without Need for Permanent BCR-ABL Inhibition

Pavel Simara, MSc, Stanislav Stejskal, MSc, Peterkova Martina, MSc, Irena Koutna, Ph.D., Zdenek Racil, MD, Jiri Mayer, MD, PhD

Blood (2010) 116 (21): 4472.

https://doi.org/10.1182/blood.V116.21.4472.4472

Published: 2010

Journal Articles

Occurrence of Chromosomal Abnormalities In Bone Marrow CD14 + monocytes of Multiple Myeloma Patients

Hana Svachova, Henrieta Greslikova, Aneta Mikulasova, Kristina Berankova, Pavel Nemec, Jiri Mayer, MD, PhD, Roman Hajek

Blood (2010) 116 (21): 2968.

https://doi.org/10.1182/blood.V116.21.2968.2968

Published: 2010

NARROW

Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life

CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry

Combination Of Lenalidomide, Dexamethasone and Cyclophosphamide as Treatment For The First Relapse Of Multiple Myeloma: Efficacy, Toxicity and Occurance Of Thyroid Abnormalities

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy?

SF3B1 Mutations Frequently Occur With Both ATM Mutations and TP53 Mutations In CLL Patients

NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911)

Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911)

Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response

Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma

Pattern of Mir-155 and PU.1 Expression in CLL/SLL and Aggressive Lymphomas

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma

Similar Efficacy of Thalidomide-Based and Bortezomib-Based Regimens In the First Relapse of 209 Multiple Myeloma Patients Previously Untreated with Novel Drugs

The Mystery of FDG-PET Avidity In Follicular Lymphoma. Does Microenvironment Play the Key Role?

Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Gene-Expression Profile of Steroid-Refractory Acute Graft-Versus-Host Disease.

Dasatinib Promotes BIM Dependent Apoptosis Via MEK/ERK without Need for Permanent BCR-ABL Inhibition

Occurrence of Chromosomal Abnormalities In Bone Marrow CD14 + monocytes of Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only